The ethics of uninsured participants accessing healthcare in biomedical research: A literature review

Clinical Trials
Volume 15 Issue 5, October 2018
http://journals.sagepub.com/toc/ctja/15/5

Ethics
The ethics of uninsured participants accessing healthcare in biomedical research: A literature review
Hae Lin Cho, Marion Danis, Christine Grady
First Published August 2, 2018; pp. 509–521
Abstract
Background/aims
Sparse literature exists on the challenges and ethical considerations of including people with limited access to healthcare, such as the uninsured and low-income, in clinical research in high-income countries. However, many ethical issues should be considered with respect to working with uninsured and low-income participants in clinical research, including enrollment and retention, ancillary care, and post-trial responsibilities. Attention to the uninsured and low-income is particularly salient in the United States due to the high rates of uninsurance and underinsurance. Thus, we conducted a scoping review on the ethical considerations of biomedical clinical research with uninsured and low-income participants in high-income countries in order to describe what is known and to pinpoint areas of needed research on this issue.
Methods
MEDLINE/PubMed, Embase, and Scopus databases were searched using terms that described main concepts of interest (e.g., uninsured, underinsured, access to healthcare, poverty, ethics, compensation, clinical research). Articles were included if they met four inclusion criteria: (1) English, (2) high-income countries context, (3) about research participants who are uninsured or low-income, which limits their access to healthcare, and in biomedical clinical research that either had a prospect of direct medical benefit or was offered to them on the basis of their ill health, and (4) recognizes and/or addresses challenges or ethical considerations of uninsured or low-income participants in biomedical clinical research.
Results
The searches generated a total of 974 results. Ultimately, 23 papers were included in the scoping review. Of 23 articles, the majority (n=19) discussed enrollment and retention of uninsured or low-income participants. Several barriers to enrolling uninsured and low-income groups were identified, including limited access to primary or preventive care; lack of access to institutions conducting trials or physicians with enough time or knowledge about trials; overall lack of trust in the government, research, or medical system; and logistical issues. Considerably fewer articles discussed treatment of these participants during the course of research (n=5) or post-trial responsibilities owed to them (n=4). Thus, we propose a research agenda that builds upon the existing literature by addressing three broad questions: (1) What is the current status of uninsured research participants in biomedical clinical research in high-income countries? (2) How should uninsured research participants be treated during and after clinical research? (3) How, if at all, should additional protections for uninsured research participants affect their enrollment?
Conclusions
This review reveals significant gaps in both data and thoughtful analysis on how to ethically involve uninsured research participants. To address these gaps, we propose a research agenda to gather needed data and theoretical analysis that addresses three broad research questions.

Global health inequalities and the need for solidarity: a view from the Global South

Developing World Bioethics
Volume 18, Issue 3  Pages: 205-306  September 2018
https://onlinelibrary.wiley.com/toc/14718847/current
SPECIAL ISSUE: AFRICAN PERSPECTIVES IN GLOBAL BIOETHICS

Global health inequalities and the need for solidarity: a view from the Global South
Mbih J. Tosam, Primus Che Chi, Nchangwi Syntia Munung, Odile Ouwe Missi Oukem‐Boyer, Godfrey B. Tangwa
Pages: 241-249
First Published: 20 December 2017

Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status

The European Journal of Public Health
Volume 28, Issue 5, 1 October 2018
https://academic.oup.com/eurpub/issue/28/5
Migration and health

Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status
Nicolas Vignier; Rosemary Dray Spira; Julie Pannetier; Andrainolo Ravalihasy; Anne Gosselin
European Journal of Public Health, Volume 28, Issue 5, 1 October 2018, Pages 904–910, https://doi.org/10.1093/eurpub/cky118

Infectious and dermatological diseases among arriving migrants on the Italian coasts

The European Journal of Public Health
Volume 28, Issue 5, 1 October 2018
https://academic.oup.com/eurpub/issue/28/5

Infectious and dermatological diseases among arriving migrants on the Italian coasts
Eugenia Di Meco; Anteo Di Napoli; Loredana Maria Amato; Antonio Fortino; Gianfranco Costanzo
European Journal of Public Health, Volume 28, Issue 5, 1 October 2018, Pages 910–916, https://doi.org/10.1093/eurpub/cky126

The growing vaccine hesitancy: exploring the influence of the internet

The European Journal of Public Health
Volume 28, Issue 5, 1 October 2018
https://academic.oup.com/eurpub/issue/28/5

The growing vaccine hesitancy: exploring the influence of the internet
Mitja Vrdelja; Alenka Kraigher; Dejan Verčič; Samo Kropivnik
European Journal of Public Health, Volume 28, Issue 5, 1 October 2018, Pages 934–939, https://doi.org/10.1093/eurpub/cky114

Accountability for the human right to health through treaty monitoring: Human rights treaty bodies and the influence of concluding observations

Global Public Health
Volume 13, 2017  Issue 11
http://www.tandfonline.com/toc/rgph20/current

Article
Accountability for the human right to health through treaty monitoring: Human rights treaty bodies and the influence of concluding observations
Benjamin Mason Meier, Marlous De Milliano, Averi Chakrabarti & Yuna Kim
Pages: 1558-1576
Published online: 04 Nov 2017
ABSTRACT
Employing novel coding methods to evaluate human rights monitoring, this article examines the influence of United Nations (UN) treaty bodies on national implementation of the human right to health. The advancement of the right to health in the UN human rights system has shifted over the past 20 years from the development of norms under international law to the implementation of those norms through national policy. Facilitating accountability for this rights-based policy implementation under the right to health, the UN Committee on Economic, Social and Cultural Rights (CESCR) monitors state implementation by reviewing periodic reports from state parties, engaging in formal sessions of ‘constructive dialogue’ with state representatives, and issuing concluding observations for state response. These concluding observations recognise the positive steps taken by states and highlight the principal areas of CESCR concern, providing recommendations for implementing human rights and detailing issues to be addressed in the next state report. Through analytic coding of the normative indicators of the right to health in both state reports and concluding observations, this article provides an empirical basis to understand the policy effects of the CESCR monitoring process on state implementation of the right to health.

Rebuilding people-centred maternal health services in post-Ebola Liberia through participatory action research

Global Public Health
Volume 13, 2017  Issue 11
http://www.tandfonline.com/toc/rgph20/current

Article
Rebuilding people-centred maternal health services in post-Ebola Liberia through participatory action research
Theresa Jones, Lara Ho, Kelvin Koffa Kun, Penelope Milsom, John Shakpeh, Ruwan Ratnayake & Rene Loewenson
Pages: 1650-1669
Published online: 31 Jan 2018
ABSTRACT
During the March 2014–January 2016 Ebola crisis in Liberia, Redemption Hospital lost 12 staff and became a holding facility for suspected cases, prompting violent hostility from the surrounding New Kru Town community, in the capital city Monrovia. Inpatient services were closed for 6 months, leaving the population without maternity care. In January 2015, Redemption reopened, but utilization was low, especially for deliveries. A key barrier was community trust in health workers which worsened during the epidemic. The New Kru Town council, Redemption Hospital, the International Rescue Committee, and Training and Research Support Centre initiated participatory action research (PAR) in July 2015 to build communication between stakeholder groups, and to identify impacts of the epidemic and shared actions to improve the system. The PAR involved pregnant women, community-based trained traditional midwives (TTMs) and traditional birth attendants (TBAs), and community leaders, as well as health workers. Qualitative data and a pre-post survey of PAR participants and community members assessed changes in relationships and maternal health services. The results indicated that Ebola worsened community-hospital relations and pre-existing weaknesses in services, but also provided an opportunity to address these when rebuilding the system through shared action. Findings suggest that PAR generated evidence and improved communication and community and health worker interaction.

 

Sharing public health data and information across borders: lessons from Southeast Asia

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 29 Sep 2018]

Research
|   29 September 2018
Sharing public health data and information across borders: lessons from Southeast Asia
The importance of data and information sharing for the prevention and control of infectious diseases has long been recognised. In recent years, public health emergencies such as avian influenza, drug-resistant malaria, and Ebola have brought renewed attention to the need for effective communication channels between health authorities, particularly in regional contexts where neighbouring countries share common health threats. However, little empirical research has been conducted to date to explore the range of factors that may affect the transfer, exchange, and use of public health data and expertise across borders, especially in developing contexts.
Authors: Marco Liverani, Srey Teng, Minh Sat Le and Richard Coke
 

Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination

International Journal of Infectious Diseases
September 2018 Volume 74, p1-144
https://www.ijidonline.com/issue/S1201-9712(18)X0007-1

Original Reports
Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
Lise Gross, Edouard Lhomme, Chloé Pasin, Laura Richert, Rodolphe Thiebaut
p83–96
Published online: July 5, 2018
 
 

Exploratory studies to inform full-scale evaluations of complex public health interventions: the need for guidance

Journal of Epidemiology & Community Health
October 2018 – Volume 72 – 10
http://jech.bmj.com/content/current

Editorial
Exploratory studies to inform full-scale evaluations of complex public health interventions: the need for guidance (11 September, 2018)
Laurence Moore, Britt Hallingberg, Daniel Wight, Ruth Turley, Jeremy Segrott, Peter Craig, Michael Robling, Simon Murphy, Sharon Anne Simpson, Graham Moore
Addressing complex public health problems, such as smoking, obesity and mental health, requires complex, often multilevel, interventions. Given the costs associated with delivering such interventions and the possibility of unanticipated harm, they need to be evaluated using the most robust methods available. It is important, where possible, that public health interventions and their proposed evaluation designs are optimised prior to being subject to an expensive evaluation of their effectiveness, through rigorous assessment of their feasibility.1 Consequently, a growing number of exploratory studies (ie, studies intended to generate the evidence needed to decide whether and how to proceed with a full-scale evaluation, also (inconsistently) referred to as ‘pilot’ or ‘feasibility’ studies) are being conducted…

The case for investing in WHO

The Lancet
Sep 29, 2018 Volume 392 Number 10153 p1089-1166 e8-e9
https://www.thelancet.com/journals/lancet/issue/current

Editorial
The case for investing in WHO
The Lancet
“This is not about only investing in an institution, it’s about investing in people, it’s about investing in a healthier, safer, fairer world”, said Director-General Tedros Adhanom Ghebreyesus at the launch of WHO’s first ever investment case. These emphatic words set the tone for an ambitious goal: to make the case for the investment needed to deliver WHO’s 5-year strategic plan, approved earlier this year—the 13th General Programme of Work, 2019–2023 (GPW13). That WHO is articulating its investment case is unprecedented and welcome. WHO’s work on global public goods (eg, norms, standards, and technical guidance) is more important than ever and is seriously under-appreciated by development partners.

If funded sufficiently, WHO believes the GPW13’s so-called triple billion targets—based on three interconnected priorities: 1 billion more people achieving universal health coverage (UHC), 1 billion more people better protected from health emergencies, and 1 billion more people enjoying better health and wellbeing—could be achieved by 2023. The investment case states that WHO, in joint action with member states and its partners, could save up to 30 million lives, add more than 100 million healthy years of life to populations worldwide, and stimulate 2–4% of economic growth in low-income and middle-income countries by 2023. The only conditionality is money. As previously estimated for GPW13 in May, 2018, to achieve these goals, the investment case estimates that WHO needs US$14·1 billion from 2019 to 2023, which includes a $10 billion base budget, $2·5 million for humani-tarian aid and emergencies, and $1·6 billion for polio eradication. WHO calls on donors for flexible and multiyear funding, the absence of which has impeded its capabilities and commitments. WHO’s current projected income is $4 billion, leaving the agency with the huge task of raising $10·1 billion for the next 5 years.

At first sight, this investment case seems compelling. An investment brochure describes the indispensable work done by WHO to support countries and improve the health of populations worldwide. It lays out a clear and valid strategic direction: to provide leadership, to ensure country impact, and to deliver global public goods. WHO will focus on activities in five specific key health areas, which support achieving the triple-billion targets: human capital, non-communicable diseases, high-impact communicable diseases, antimicrobial resistance, and healthy environment. Surprisingly, the case provides little concrete detail about how WHO will use these funds to deliver on its stated goals. Perplexing is the disconnect between the claims of impact in the investment case and of those in the accompanying technical report, which estimates the health impacts and economic returns for universal health coverage (UHC), health emergencies, and intersectoral action based on a collective global investment—and not for specific investments in WHO. Thus, the UHC return of 25·1 million deaths averted is based on a global investment of $1·1 trillion as set out in the technical report. However, the WHO investment case seems to suggest that investing $14·1 billion in WHO alone will generate these returns. The technical report seems to bear little relation to the investment case for WHO.

A valuable contribution of the investment case would have been to clearly articulate what WHO will actually do in its three priority areas and where its comparative advantage lies: global public goods and normative work, emergency preparedness, and support to countries in developing the health policies needed to achieve the Sustainable Development Goals (SDGs). At a time when WHO is competing for limited donor resources against other institutions, such as The Global Fund to Fight AIDS, Tuberculosis and Malaria and Gavi, The Vaccine Alliance, a clear explanation of how additional investments will deliver the goals set out in the investment case seems crucial. A more precise analysis could have made the case for a chronically underfunded but desperately useful and overlooked part played by WHO: that of providing global public goods, which need to be reinforced to reach the SDGs and respond to old and emerging global health threats.

WHO’s historic and institutional strengths lie in responding to the urgent needs of its member states. But during the past decade, WHO’s budget has been tied to donor conditionalities and has failed to grow in real terms. Therefore, it is right that WHO is calling on donors to strengthen the agency’s global, regional, and country capacities to take advantage of the opportunities that exist for improving human health. Sharpening the investment case still further will go a long way to fulfil that opportunity.

13th General Programme of Work (2019-2023) see White paper 2018
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32289-X/fulltext

 

Addressing the fragmentation of global health: the Lancet Commission on synergies between universal health coverage, health security, and health promotion

The Lancet
Sep 29, 2018 Volume 392 Number 10153 p1089-1166 e8-e9
https://www.thelancet.com/journals/lancet/issue/current

Comment
Addressing the fragmentation of global health: the Lancet Commission on synergies between universal health coverage, health security, and health promotion
Gorik Ooms, Trygve Ottersen, Albrecht Jahn, Irene Akua Agyepong
Global health is fragmented. Many stakeholders pursue their own agenda while neglecting other important goals for global health. Some global health actors, for example, focus on strengthening health security without attention to universal health coverage (UHC), primary health care (PHC), and population-based health promotion. Prevention is a key part of PHC and UHC, but efforts to ensure PHC or make progress towards UHC often do not include population-based prevention efforts. Proponents often use broad definitions of their agenda in declarations and statements, while applying much narrower definitions in practice. If these tensions are not addressed, fragmentation will continue to make local, national, and global efforts inefficient and opportunities will be lost in terms of lives saved and quality of life.

Repositioning Africa in global knowledge production

The Lancet
Sep 29, 2018 Volume 392 Number 10153 p1089-1166 e8-e9
https://www.thelancet.com/journals/lancet/issue/current

Viewpoint
Repositioning Africa in global knowledge production
Sharon Fonn, Laban Peter Ayiro, Philip Cotton, Adam Habib, Peter Mulwa Felix Mbithi, Alfred Mtenje, Barnabas Nawangwe, Eyitope O Ogunbodede, Idowu Olayinka, Frederick Golooba-Mutebi, Alex Ezeh
Introduction
Sub-Saharan Africa accounts for 13·5% of the global population but less than 1% of global research output. In 2008, Africa produced 27 000 published papers—the same number as The Netherlands. Informed by a nuanced understanding of the causes of the current scenario, we propose action that should be taken by African universities, governments, and development partners to foster the development of research-active universities on the continent…

 

A new era for tuberculosis?

Lancet Global Health
Oct 2018 Volume 6 Number 10 e1045-e1138
http://www.thelancet.com/journals/langlo/issue/current

Editorial
 A new era for tuberculosis?
The Lancet Global Health
In his keynote speech at this year’s Consortium of Universities for Global Health meeting in March, the former UN Secretary-General’s Special Envoy for HIV/AIDS in Africa, Stephen Lewis, delivered a blistering attack on the global response to tuberculosis. Citing it as one of three glaring examples of the consequences of inequalities worldwide (the others being climate change and conflict), he pointed to the 280-fold difference in tuberculosis incidence between Canadian Inuits and the non-Indigenous Canadian-born population, and to the “callous starvation” of funding for multidrug-resistant (MDR) disease in India despite the country’s massive burden.

Tuberculosis is the leading infectious killer globally and disproportionately affects disadvantaged populations—eg, homeless people, prisoners, migrants, people living with HIV. It therefore rightly maintains its place in the Sustainable Development Goals, whose guiding principle is to leave no one behind. The WHO End TB Strategy fleshes out these targets (ie, to reduce deaths by 95% and new cases by 90% between 2015 and 2035, and to ensure that no family suffers catastrophic expenses). Yet current progress is not commensurate with these ambitious aims. Stephen Lewis went so far as to call Narendra Modi’s assertion that India would eradicate tuberculosis by 2025 “nonsense”. This month sees an opportunity to change things for the better. On Sept 26, heads of state will gather in New York at the first UN High-Level Meeting (HLM) on tuberculosis with the aim of uniting to reboot progress and culminating in an “ambitious political declaration”. Will it make any difference?

UN HLMs are convened when there is a perceived need to engage all sectors in order to effect developmental, social, and economic change. Tuberculosis is indeed the epitome of a developmental, social, and economic problem. As Priya Shete and colleagues point out in a Comment published today, “Being poor increases the risk of falling sick with tuberculosis. Falling sick with tuberculosis also leads to impoverishment that can trigger a downward spiral of worsening health, ongoing tuberculosis transmission, and crippling medical expenses which further entrench poverty.” Referencing a modelling study published in The Lancet Global Health earlier this year, which estimated that expanding social protection coverage could reduce the global incidence of tuberculosis by 76% by 2035, Shete and colleagues call for integration of social protection with tuberculosis care within policies, programmes, and research.

Parallel efforts to highlight the importance of access to affordable tuberculosis drugs, particularly for MDR strains, have been ongoing ahead of the HLM. Earlier drafts of the political declaration—the key outcome document of the HLM—contained reference to the full use of flexibilities in intellectual property rules geared towards maximising access. Yet, under pressure from the USA and others, the final draft saw these provisions weakened. South Africa, which the same month became the first country in the world to roll out bedaquiline to all eligible patients with MDR tuberculosis (and at a reduced price) protested and negotiations were reopened. As we went to press, it was unclear whether the text would be reinstated.

Last month, WHO issued a rapid communication summarising key changes it will be making to its guidelines on the treatment of MDR tuberculosis. These include prioritising newer oral drugs, including bedaquiline, over injectables. The changes are justified by an individual patient data meta-analysis published in The Lancet last week, which found that “the traditionally used drugs for treatment of multidrug-resistant tuberculosis, especially oral second-line drugs and even the injectable drugs, appear to be less effective than the later generation fluoroquinolones, linezolid, bedaquiline, clofazimine, and possibly the carbapenems”. New trials are also underway to find shorter, less debilitating, treatment regiments for MDR tuberculosis, including the SimpliciTB and endTB trials.

There are many priorities in the complex and centuries-long fight against this cruel disease. But to suggest, as did a US representative at the recent civil society hearing ahead of the HLM, that global efforts should focus on improving health systems and new tools, rather than being “distracted, as we so often are, into a discussion of access to medicines, intellectual property flexibilities, or compulsory licensing” is plainly absurd. New tools include new (expensive) medicines and health systems cannot improve if WHO-recommended regimens cannot be afforded. Will the HLM make a difference? Not as long as commercial protectionism trumps social justice.

 

Ending cholera for all

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Editorial
Ending cholera for all
The Lancet Infectious Diseases
Cholera, a bacterial diarrhoeal infection caused by Vibrio cholerae and transmitted by the faecal–oral route, is not a disease recently associated with Algeria. Indeed, in a report published by the Global Task Force on Cholera Control (GTFCC) on Oct 3, 2017, Ending Cholera—A Global Roadmap to 2030, Algeria is not listed among the 47 countries affected by the disease. But, having had no cases since 1994, from Aug 7–30, 2018, 74 confirmed cholera cases including two deaths were reported in six northern and coastal districts of the country. V cholerae has been isolated from a natural water source, not connected to the public water system, in the region of Tipaza. How the water source became contaminated is unclear; spread of the disease to other regions of Algeria via contaminated fruit and vegetables is a possibility. The outbreak in Algeria, although small in scale, is a timely reminder that cholera is an epidemic infection that can reappear after disease-free decades in circumstances of unsafe water supply and sanitation.

The vulnerability of people to cholera from unsafe drinking water sources was emphasised in a commitment made by African health ministers on Aug 28—at the same time as the Algeria outbreak—to implement strategies to end cholera in the Africa region by 2030. 17 African countries reported more than 150 000 cholera cases in 2017, and currently eight countries on the continent are dealing with outbreaks. The commitment made by African governments is an endorsement of the strategies set out in the Global Roadmap published last year. This plan aims to support countries to reduce cholera deaths by 90% by 2030, with up to 20 countries having eliminated the disease as a public health threat.

As we noted in an Editorial in 2017, cholera is a disease of poor and vulnerable populations, notably in conflict situations and where sanitation and hygiene are inadequate. Known pandemics of cholera, originating from south and southeast Asia, have occurred since the early 19th century, affecting all parts of the world. However, improvements in safe water and sewage disposal eliminated the disease from high-income countries during the 20th century. The outbreaks currently affecting the world, which kill an estimated 107 000 people per year, are remnants of the seventh pandemic, which began in Indonesia in 1961. That 57 years later—despite having the knowledge and means to hand to effect change—the disease is still a threat to human health marks a failure of global public health.

The Global Roadmap admits that the GTFCC, which was created in 1992, “became inactive after elimination of cholera in the Americas” in the early 2000s. It took a World Health Assembly resolution in 2011 to revitalise cholera control efforts. A paper published online by the Journal of Infectious Diseases on Sept 1, notes four factors that have converged to make cholera elimination feasible: increased emphasis on equity, as exemplified by the Sustainable Development Goals, with occurrence of cholera indicative of people’s access to basic water and sanitation services; the technical capacity to detect cholera quickly; availability of oral cholera vaccine (OCV) in sufficient quantity to manage large outbreaks; and an increasing degree of politic commitment in affected countries (as shown by the African health ministers’ declaration).

The objectives for 2030 in the Global Roadmap are based on three axes: early detection and response to contain outbreaks through, for example, surveillance systems, prepositioning essential supplies, monitoring water sources, and mass vaccination campaigns; targeting cholera hotspots through, in addition to the above, providing sustainable safe water and sanitation networks and building the capacity of health-care systems; and effective coordination of technical support and resources at local and global levels.

Of the various resources needed to achieve global cholera control, the availability of OCVs is encouraging, with 25 million doses predicted to be in the stockpile this year. And there is evidence of national political commitment, with the Government of Uganda launching on Sept 5, an OCV campaign targeting 1·6 million people living in cholera hotspots. But ultimately cholera control requires civil engineering through building a robust infrastructure of clean water supply and sewage disposal and treatment. The initial investment may seem great, but it is less so when considered per head of population over decades, for the reduction in other water-related diseases, and for the increased wellbeing and productivity of a country’s people.

Measles: is a new vaccine approach needed?

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Comment
Measles: is a new vaccine approach needed?
Cléa Melenotte, Christine Zandotti, Philippe Gautret, Philippe Parola, Didier Raoult
WHO’s goal was to eradicate measles in the 20th century, but measles still represents a public health challenge in the developing world, and in Europe, where epidemic outbreaks are regularly reported

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Articles
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
Wilbur H Chen, Kathleen M Neuzil, C Rebecca Boyce, Marcela F Pasetti, Mardi K Reymann, Lionel Martellet, Nancy Hosken, F Marc LaForce, Rajeev M Dhere, Sambhaji S Pisal, Amol Chaudhari, Prasad S Kulkarni, Ray Borrow, Helen Findlow, Valerie Brown, Megan L McDonough, Len Dally, Mark R Alderson

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Review
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Natalie I Mazur, Deborah Higgins, Marta C Nunes, José A Melero, Annefleur C Langedijk, Nicole Horsley, Ursula J Buchholz, Peter J Openshaw, Jason S McLellan, Janet A Englund, Asuncion Mejias, Ruth A Karron, Eric AF Simões, Ivana Knezevic, Octavio Ramilo, Pedro A Piedra, Helen Y Chu, Ann R Falsey, Harish Nair, Leyla Kragten-Tabatabaie, Anne Greenough, Eugenio Baraldi, Nikolaos G Papadopoulos, Johan Vekemans, Fernando P Polack, Mair Powell, Ashish Satav, Edward E Walsh, Renato T Stein, Barney S Graham, Louis J Bont in collaboration with Respiratory Syncytial Virus Network (ReSViNET) Foundation

Experimental infection of human volunteers

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Experimental infection of human volunteers
Meta Roestenberg, Marie-Astrid Hoogerwerf, Daniela M Ferreira, Benjamin Mordmüller, Maria Yazdanbakhsh
Summary
Controlled human infection (CHI) trials, in which healthy volunteers are experimentally infected, can accelerate the development of novel drugs and vaccines for infectious diseases of global importance. The use of CHI models is expanding from around 60 studies in the 1970s to more than 120 publications in this decade, primarily for influenza, rhinovirus, and malaria. CHI trials have provided landmark data for several registered drugs and vaccines, and have generated unprecedented scientific insights. Because of their invasive nature, CHI studies demand critical ethical review according to established frameworks. CHI-associated serious adverse events are rarely reported. Novel CHI models need standardised safety data from comparable CHI models to facilitate evidence-based risk assessments, as well as funds to produce challenge inoculum according to regulatory requirements. Advances such as the principle of controlled colonisation, the expansion of models to endemic areas, and the use of genetically attenuated strains will further broaden the scope of CHI trials.

The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy

Lancet Infectious Diseases
Oct 2018 Volume 18 Number 10 p1047-1160 e295-e338
http://www.thelancet.com/journals/laninf/issue/current

Personal View
The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy
Kathryn B Anderson, Timothy P Endy, Stephen J Thomas
Summary
Dengue virus infections cause a substantial public health burden in tropical and subtropical regions. A single dengue vaccine has been approved by regulatory authorities in 19 countries, but concerns regarding vaccine safety in people who are dengue naive at the time of immunisation has introduced uncertainty into the vaccine’s future. As other dengue vaccines complete or enter large-scale efficacy trials, we argue that foundational work by Sabin, historic epidemiological observations of dengue outbreaks, and prospective cohort studies in Asia and the Americas indicate that modifications must be made to the methods of assessing dengue vaccines. In this Personal View, we review and relate previous data that supports a dynamic role of cross-protective dengue immunity to the goals and challenges of measuring and interpreting dengue vaccine immunogenicity, efficacy, and safety in clinical trials. We suggest that for partly protective vaccines, temporary cross-protective immunity could lead to overestimation of vaccine safety and efficacy in the early years following vaccination. We recommend that assessment of dengue vaccines should span several years, involve active surveillance to clinically characterise incident infections and regular blood draws to define kinetic changes in immunological profiles, and include sample sizes that are large enough to support detailed analyses of vaccine trial subgroups, such as individuals who are dengue naive.

Introduction to the Special Issue on Taking Home Visiting to Scale: Findings from the Maternal, Infant, and Early Childhood Home Visiting Program State-Led Evaluations

Maternal and Child Health Journal
Volume 22, Issue 1 Supplement, October 2018
https://link.springer.com/journal/10995/22/1/suppl/page/1
Special Issue: Taking Home Visiting to Scale: Findings from the Maternal, Infant, and Early Childhood Home Visiting Program State-Led Evaluations
Issue Editors: Nicole Denmark, Kyle Peplinski, Mariel Sparr, Judy Labiner-Wolfe, Susan Zaid,
Pooja Gupta, Kassie Mae Miller

Editorial
Introduction to the Special Issue on Taking Home Visiting to Scale: Findings from the Maternal, Infant, and Early Childhood Home Visiting Program State-Led Evaluations
Nicole Denmark, Kyle Peplinski, Mariel Sparr
Abstract
The Maternal, Infant and Early Childhood Home Visiting (MIECHV) Program is a two-generation approach to supporting healthy families through home visits during pregnancy and early childhood. All states and territories receiving MIECHV funding are encouraged to evaluate their programs. This special issue highlights evaluations from 11 awardees—Arkansas, Florida, Illinois, Iowa, Maryland, Massachusetts, Michigan, New Jersey, Oregon, Pennsylvania, and Tennessee. With the wide expansion of home visiting since the onset of MIECHV, the state-led evaluations contribute to the understanding of replication and scale-up of evidence-based home visiting.

Future Directions for Cost-effectiveness Analyses in Health and Medicine

Medical Decision Making (MDM)
Volume 38 Issue 7, October 2018
http://mdm.sagepub.com/content/current

Original Articles
Future Directions for Cost-effectiveness Analyses in Health and Medicine
Peter J. Neumann, David D. Kim, Thomas A. Trikalinos, Mark J. Sculpher, Joshua A. Salomon, Lisa A. Prosser, Douglas K. Owens, David O. Meltzer, Karen M. Kuntz, Murray Krahn, David Feeny, Anirban Basu, Louise B. Russell, Joanna E. Siegel, Theodore G. Ganiats, Gillian D. Sanders
Abstract
Objectives. In 2016, the Second Panel on Cost-effectiveness in Health and Medicine updated the seminal work of the original panel from 2 decades earlier. The Second Panel had an opportunity to reflect on the evolution of cost-effectiveness analysis (CEA) and to provide guidance for the next generation of practitioners and consumers. In this article, we present key topics for future research and policy.
Methods. During the course of its deliberations, the Second Panel discussed numerous topics for advancing methods and for improving the use of CEA in decision making. We identify and consider 7 areas for which the panel believes that future research would be particularly fruitful. In each of these areas, we highlight outstanding research needs. The list is not intended as an exhaustive inventory but rather a set of key items that surfaced repeatedly in the panel’s discussions. In the online Appendix, we also list and expound briefly on 8 other important topics.
Results. We highlight 7 key areas: CEA and perspectives (determining, valuing, and summarizing elements for the analysis), modeling (comparative modeling and model transparency), health outcomes (valuing temporary health and path states, as well as health effects on caregivers), costing (a cost catalogue, valuing household production, and productivity effects), evidence synthesis (developing theory on learning across studies and combining data from clinical trials and observational studies), estimating and using cost-effectiveness thresholds (empirically representing 2 broad concepts: opportunity costs and public willingness to pay), and reporting and communicating CEAs (written protocols and a quality scoring system).
Conclusions. Cost-effectiveness analysis remains a flourishing and evolving field with many opportunities for research. More work is needed on many fronts to understand how best to incorporate CEA into policy and practice

Outbreaks in a Rapidly Changing Central Africa — Lessons from Ebola

New England Journal of Medicine
September 27, 2018  Vol. 379 No. 13
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Outbreaks in a Rapidly Changing Central Africa — Lessons from Ebola
Vincent J. Munster, Ph.D., Daniel G. Bausch, M.D., Emmie de Wit, Ph.D., Robert Fischer, Ph.D.,
Gary Kobinger, Ph.D., César Muñoz-Fontela, Ph.D., Sarah H. Olson, Ph.D., Stephanie N. Seifert, Ph.D., Armand Sprecher, M.D., Francine Ntoumi, Ph.D., Moses Massaquoi, M.D., and Jean-Vivien Mombouli, Ph.D.
[Initial text]
West and Central Africa are experiencing explosive growth in urban populations, economic activities, and connectivity. The recent Ebola virus epidemic in West Africa demonstrated the vulnerability of the local health care infrastructure to newly emerging infectious diseases. Two key factors contributing to the epidemic’s unprecedented size were growth-related: large urban populations that overwhelmed the public health infrastructure of these resource-poor countries and the extensive spatial and technological connectivity of the population.1 These factors portend an increased risk in Central Africa of emerging infectious diseases caused by both known and unknown pathogens. Such unwelcome side effects of rapid growth can be mitigated only by strengthening the health care infrastructure, including diagnostic and clinical capacity, to meet the health care needs of the population; investment in the training of health care workers and African scientists; expansion of research capacity; development of disease-surveillance programs focused on humans, livestock, and wildlife; and rapid deployment of control measures when outbreaks occur…

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 29 Sep 2018]

Measuring Mosquito-borne Viral Suitability in Myanmar and Implications for Local Zika Virus Transmission
September 28, 2018 · Research Article
Introduction: In South East Asia, mosquito-borne viruses (MBVs) have long been a cause of high disease burden and significant economic costs. While in some SEA countries the epidemiology of MBVs is spatio-temporally well characterised and understood, in others such as Myanmar our understanding is largely incomplete.
Materials and Methods: Here, we use a simple mathematical approach to estimate a climate-driven suitability index aiming to better characterise the intrinsic, spatio-temporal potential of MBVs in Myanmar.
Results: Results show that the timing and amplitude of the natural oscillations of our suitability index are highly informative for the temporal patterns of DENV case counts at the country level, and a mosquito-abundance measure at a city level. When projected at fine spatial scales, the suitability index suggests that the time period of highest MBV transmission potential is between June and October independently of geographical location. Higher potential is nonetheless found along the middle axis of the country and in particular in the southern corridor of international borders with Thailand.
Discussion: This research complements and expands our current understanding of MBV transmission potential in Myanmar, by identifying key spatial heterogeneities and temporal windows of importance for surveillance and control. We discuss our findings in the context of Zika virus given its recent worldwide emergence, public health impact, and current lack of information on its epidemiology and transmission potential in Myanmar. The proposed suitability index here demonstrated is applicable to other regions of the world for which surveillance data is missing, either due to lack of resources or absence of an MBV of interest.

Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 29 Sep 2018)

Research Article
Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study
Hepatitis E Virus (HEV) is the leading cause of acute viral hepatitis globally. Symptomatic infection is associated with case fatality rates of ~20% in pregnant women and it is estimated to account for ~10,000 annual pregnancy-related deaths in southern Asia alone. Recently, large and well-documented outbreaks with high mortality have occurred in displaced population camps in Sudan, Uganda and South Sudan. However, the epidemiology of HEV is poorly defined, and the value of different immunisation strategies in outbreak settings uncertain. We aimed to estimate the critical epidemiological parameters for HEV and to evaluate the potential impact of both reactive vaccination (initiated in response to an epidemic) and pre-emptive vaccination.
Ben S. Cooper, Lisa J. White, Ruby Siddiqui
Research Article | published 25 Sep 2018 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0006807

Ethical issues in using the internet to engage participants in family and child research: A scoping review

PLoS One
http://www.plosone.org/
[Accessed 29 Sep 2018]

Research Article
Ethical issues in using the internet to engage participants in family and child research: A scoping review
Stacey Hokke, Naomi J. Hackworth, Nina Quin, Shannon K. Bennetts, Hnin Yee Win, Jan M. Nicholson, Lawrie Zion, Jayne Lucke, Patrick Keyzer, Sharinne B. Crawford
Research Article | published 27 Sep 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0204572
Abstract
Background
The internet is an increasingly popular tool in family and child research that is argued to pose new ethical challenges, yet few studies have systematically assessed the ethical issues of engaging parents and children in research online. This scoping review aims to identify and integrate evidence on the ethical issues reported when recruiting, retaining and tracing families and children in research online, and to identify ethical guidelines for internet research.
Methods
Academic literature was searched using electronic academic databases (Scopus, PsycINFO, Embase, ERIC, CINAHL and Informit) and handsearching reference lists for articles published in English between January 2006 and February 2016. Grey literature was searched using Google to identify relevant ethical guidelines.
Results
Sixty-five academic articles were included after screening 3,537 titles and abstracts and 205 full-text articles. Most articles reported using the internet to recruit participants (88%) with few reporting online retention (12%) or tracing (10%). Forty percent commented on ethical issues; the majority did not discuss ethics beyond general consent or approval procedures. Some ethical concerns were specific to engaging minors online, including parental consent, age verification and children’s vulnerability. Other concerns applied when engaging any research participant online, including privacy and confidentiality, informed consent and disparities in internet access. Five professional guidelines and 10 university guidelines on internet research ethics were identified. Few academic articles (5%) reported using these guidelines.
Conclusions
Engaging families and children in research online introduces unique challenges requiring careful consideration. While researchers regarded themselves as responsible for ensuring research is conducted ethically, lack of use of available guidelines and limited academic literature suggests internet research is occurring without suitable guidance. We recommend broad dissemination of ethical guidelines and encourage researchers to report the methodological and ethical issues of using the internet to engage families and children in research.

 

Advantages and disadvantages of channeling Gavi’s health system strengthening funds through health partners, a case study

PLoS One
http://www.plosone.org/
[Accessed 29 Sep 2018]

Research Article
Advantages and disadvantages of channeling Gavi’s health system strengthening funds through health partners, a case study
Charbel El Bcheraoui, Yodé Miangotar, Farah Daoud, Ellen Squire, Honoré Mimche
Research Article | published 26 Sep 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0203647

Effects of cultural cues on perceptions of HPV vaccination messages among parents and guardians of American Indian youth

Preventive Medicine
Volume 115 Pages 1-156 (October 2018)
https://www.sciencedirect.com/journal/preventive-medicine/vol/114/suppl/C

Research article Abstract only
Effects of cultural cues on perceptions of HPV vaccination messages among parents and guardians of American Indian youth
Marco Yzer, Kristine Rhodes, Meggan McCann, Jessica Harjo, … Sarah E. Gollust
Pages 104-109

Capacity for evidence-informed policymaking across Europe: development and piloting of a multistakeholder survey

Public Health
October 2018 Volume 163, In Progress
http://www.publichealthjrnl.com/current

Original Research
Capacity for evidence-informed policymaking across Europe: development and piloting of a multistakeholder survey
Visram, D.J. Hunter, T. Kuchenmüller

Published online: August 6, 2018
Highlights
:: Public health policies still tend not to be well-informed by research evidence.
:: Few studies have examined capacities for evidence-informed policymaking.
:: We developed and piloted a multicountry, multistakeholder survey.
:: However, we found few examples of the application and impact of research evidence.
:: Next steps include revising and implementing the survey across Europe.

Lógicas de transformación de los sistemas de salud en América Latina y resultados en acceso y cobertura de salud [Types of health systems reforms in Latin America and results in health access and coverage]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101

Recently Published Articles
Lógicas de transformación de los sistemas de salud en América Latina y resultados en acceso y cobertura de salud [Types of health systems reforms in Latin America and results in health access and coverage]
Ernesto Báscolo, Natalia Houghton y Amalia Del Riego
Original research | PDF: https://doi.org/10.26633/RPSP.2018.126 | Published 24 September 2018

La atención primaria de salud en la Región de las Américas a 40 años de la Declaración de Alma-Ata [Primary health care in the Region of the Americas 40 years after the Alma-Ata Declaration]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101

La atención primaria de salud en la Región de las Américas a 40 años de la Declaración de Alma-Ata [Primary health care in the Region of the Americas 40 years after the Alma-Ata Declaration]
Gisele Almeida, Osvaldo Artaza, Nora Donoso and Ricardo Fábrega
Opinion and analysis | PDF: https://doi.org/10.26633/RPSP.2018.104 | Published 24 September 2018

Cancer prevention: Molecular and epidemiologic consensus

Science        
28 September 2018 Vol 361, Issue 6409
http://www.sciencemag.org/current.dtl
Special Issue – Genes in Development

Policy Forum
Cancer prevention: Molecular and epidemiologic consensus
By Mingyang Song, Bert Vogelstein, Edward L. Giovannucci, Walter C. Willett, Cristian Tomasetti
Science28 Sep 2018 : 1317-1318 Restricted Access
Research in many fields emphasizes the value of prevention
Summary
Prevention of any disease can occur at two levels: (i) avoiding or reducing risk factors coupled with increases in protective factors (primary prevention, which is preferable when it can be practiced) and (ii) detection and intervention early in the course of disease evolution (secondary prevention). But despite substantial epidemiologic data showing that a large proportion of cancers and cancer deaths are preventable, decreases in cancer mortality rates in developed countries have lagged far behind decreases in mortality rates from heart disease (1), another major disease amenable to prevention (for example, 18 versus 68% decrease, respectively, between 1969 and 2013 in the United States) (2). We believe that one main factor explaining the relatively modest reduction in mortality is the limited support for cancer prevention research, which receives only 2 to 9% of global cancer research funding (3). As a United Nations (UN) High-Level Meeting begins this week to review efforts to combat noncommunicable diseases, a key question is how to prioritize resources to realize the potential of cancer prevention. http://www.sciencemag.org/about/science-licenses-journal-article-reuse

Ethics-based global health research for all, including women, children, indigenous people, LGBTQI, people with disabilities, refugees and other relevant stakeholders, especially in least developing countries and small island developing states in the Global South

Social Science & Medicine
Volume 214 Pages 1-214 (October 2018)
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/212/suppl/C

Discussion
Ethics-based global health research for all, including women, children, indigenous people, LGBTQI, people with disabilities, refugees and other relevant stakeholders, especially in least developing countries and small island developing states in the Global South
Lucilla Spini
Pages 167-170

A review of recent publication trends from top publishing countries

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 29 Sep 2018]

Research
A review of recent publication trends from top publishing countries
Evidence-based medicine relies on current best evidence from the medical literature, the patient’s history, and the clinician’s own experience to provide the best care for patients. Systematic reviews and meta…
Authors: Paul Fontelo and Fang Liu
Citation: Systematic Reviews 2018 7:147
Published on: 27 September 2018

Acquisition of enteric pathogens by pilgrims during the 2016 Hajj pilgrimage: A prospective cohort study

Travel Medicine and Infectious Diseases
September-October, 2018  Volume 25
http://www.travelmedicinejournal.com/

Original Research
Acquisition of enteric pathogens by pilgrims during the 2016 Hajj pilgrimage: A prospective cohort study
Doudou Sow, Fabiola Dogue, Sophie Edouard, Tassadit Drali, Ségolène Prades, Emilie Battery, Saber Yezli, Badriah Alotaibi, Cheikh Sokhna, Didier Raoult, Philippe Parola, Philippe Gautret
Vol. 25, p26–30
Published online: May 30, 2018

Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review

Travel Medicine and Infectious Diseases
September-October, 2018  Volume 25
http://www.travelmedicinejournal.com/

Systematic Review
Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review
Egon Isenring, Jan Fehr, Nejla Gültekin, Patricia Schlagenhauf
Vol. 25, p65–76
Published online: April 24, 2018

Should travelers be offered vaccination against the dengue virus?

Travel Medicine and Infectious Diseases
September-October, 2018  Volume 25
http://www.travelmedicinejournal.com/

Should travelers be offered vaccination against the dengue virus?
Emilie Javelle, Asma Al Balushi, Sanne Jespersen, Seif Al-Abri, Philippe Gautret, Eskild Petersen
Publication stage: In Press Accepted Manuscript
Published online: September 26, 2018
Abstract
Dengue fever is expanding into new areas due to travel, climate change, urbanization, and the widening geographic range of the main vectors Ae.aegypti and Ae.albopictus [1].The newly licensed, tetravalent vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur,has surprisingly been shown to increase the risk of severe dengue virus disease in persons not previously exposed to dengue virus. This has halted the roll out of the vaccine in endemic areas. In this editorial we argue that the new vaccine may have a place for travellers from non-endemic to endemic areas, who have previously experienced a dengue virus infection.

Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study

Vaccine
Volume 36, Issue 41 Pages 6039-6248 (1 October 2018)
https://www.sciencedirect.com/journal/vaccine/vol/36/issue/41

Research article   Abstract only
Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study
Holly C. Groom, Stephanie A. Irving, Padma Koppolu, Ning Smith, … Allison L. Naleway
Pages 6111-6116

Research article Abstract only Evaluation of a school entry immunization record check strategy in 4 counties of Ningxia and Hubei provinces, China Mengjuan Duan, Jingshan Zheng, Liwei Zhou, Lei Wang, … Qiyou Xiao Pages 6231-6236

Vaccine
Volume 36, Issue 41 Pages 6039-6248 (1 October 2018)
https://www.sciencedirect.com/journal/vaccine/vol/36/issue/41

Research article   Abstract only
Evaluation of a school entry immunization record check strategy in 4 counties of Ningxia and Hubei provinces, China
Mengjuan Duan, Jingshan Zheng, Liwei Zhou, Lei Wang, … Qiyou Xiao
Pages 6231-6236

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

International Journal for Equity in Health
2018 17:126   Published: 24 September 2018

Commentary Open Access
Are we entering a new era for qualitative research? Using qualitative evidence to support guidance and guideline development by the World Health Organization
S Lewin, C Glenton
Abstract
Qualitative approaches are one of several methodologies utilised within the social sciences. New developments within qualitative methods are widening the opportunities for using qualitative evidence to inform health policy and systems decisions. In this commentary, we discuss how, in our work with the World Health Organization (WHO), we have explored ways of broadening the types of evidence used to develop evidence-informed guidance for health systems.

Health systems decisions are commonly informed by evidence on the effectiveness of health system interventions. However, decision makers and other stakeholders also typically have additional questions, including how different stakeholders value different outcomes, the acceptability and feasibility of different interventions and the impacts of these interventions on equity and human rights. Evidence from qualitative research can help address these questions, and a number of WHO guidelines are now using qualitative evidence in this way. This growing use of qualitative evidence to inform decision making has been facilitated by recent methodological developments, including robust methods for qualitative evidence syntheses and approaches for assessing how much confidence to place in findings from such syntheses. For research evidence to contribute optimally to improving and sustaining the performance of health systems, it needs to be transferred easily between different elements of what has been termed the ‘evidence ecosystem’. This ecosystem includes primary and secondary evidence producers, guidance developers and those implementing and evaluating interventions to strengthen health systems. We argue that most of the elements of an ecosystem for qualitative evidence are now in place – an important milestone that suggests that we are entering a new era for qualitative research. However, a number of challenges and constraints remain. These include how to build stronger links between the communities involved in the different parts of the qualitative evidence ecosystem and the need to strengthen capacity, particularly in low and middle income countries, to produce and utilise qualitative evidence and decision products informed by such evidence. We invite others who want to support the wider use of qualitative evidence in decision processes to look for opportunities in their settings to put this into practice.

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 29 Sep 2018
[No new, unique, relevant content]
 

BBC
http://www.bbc.co.uk/
Accessed 29 Sep 2018
29 Sep 2018
The History Hour: The Creation of the Cervical Cancer Vaccine
[Audio]…The creation of the cervical cancer vaccine, other topics…
 

The Economist
http://www.economist.com/
Accessed 29 Sep 2018
Influenza – The centenary of the 20th century’s worst catastrophe
“Spanish flu” probably killed more people than both world wars combined
Sep 27th 2018
 

Financial Times
http://www.ft.com/home/uk
Accessed 29 Sep 2018
[No new, unique, relevant content]

Forbes
http://www.forbes.com/
Accessed 29 Sep 2018
[No new, unique, relevant content]

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 29 Sep 2018
Health Without Wealth
The world has been getting healthier in ways that should make us worry.
26 September 2018
By Thomas J. Bollyky
…The lesson is not that progress against disease is not worthwhile or that it came too soon to developing nations. Nor is it that the war against microbes is over: global health threats, such as pandemic flu and antibiotic-resistant bugs, still loom. There is no worthier goal than reducing unnecessary pain and preventing deaths, especially among children. And a dire future is not inevitable; healthier populations can still lead poor countries to prosperity, just as they did in the past. To make sure that they do, the world needs to pair global health aid with investments that can help countries improve their health-care systems…At the same time, developing countries need to devote more resources to their cities and health-care systems…

Foreign Policy
http://foreignpolicy.com/
Accessed 29 Sep 2018
Argument
The Next Pandemic Will Be Arriving Shortly
Deadly diseases like Ebola and the avian flu are only one flight away. The U.S. government must start taking preparedness seriously.
By Lisa Monaco, Vin Gupta
| September 28, 2018, 5:01 PM

The Guardian
http://www.guardiannews.com/
Accessed 29 Sep 2018
[No new, unique, relevant content]
 

New Yorker
http://www.newyorker.com/
Accessed 29 Sep 2018
[No new, unique, relevant content]

 
New York Times
http://www.nytimes.com/
Accessed 29 Sep 2018
Opinion
Letters
For Progress on Vaccine Development
A researcher says we need a moonshot-level effort
To the Editor:

Money Needed to Develop Vaccines, Study Says” (Science Times, Global Health, Sept. 11) discussed the critical need to increase funding for developing vaccines for significant global public health threats.

I worked for more than 25 years trying to develop a vaccine for H.I.V., and the reality is that traditional approaches to vaccine development have now hit a critical impasse. Despite decades of work and billions in investment, vaccines for H.I.V., tuberculosis, cancers, neurodegenerative and autoimmune diseases have evaded our best efforts, and we remain woefully unprepared for the next pandemic.
This lack of progress is largely due to a fundamental gap in our understanding of how our immune system prevents and controls disease. Rather than primarily funding individual efforts on single diseases, we need significant resources focused on decoding the human immune system, on a moonshot-level scale of the Human Genome Project.
Technological advances in biomedicine and computer sciences have provided the tools necessary to undertake this effort, but we must act before these diseases take an even greater toll.
Wayne Koff
New York
The writer is president and chief executive of the Human Vaccines Project, a nonprofit.

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 29 Sep 2018
[No new, unique, relevant content]

Washington Post
http://www.washingtonpost.com/
Accessed 29 Sep 2018
Flu broke records for deaths, illnesses in 2017-2018, new CDC numbers show
Lena H. Sun Sep 27, 2018

Ebola is back. Is Africa ready?
27 September 2018.

Think Tanks et al

 Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 29 Sep 2018
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center
Accessed 29 Sep 2018
[No new relevant content]

CSIS
https://www.csis.org/
Accessed 29 Sep 2018
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 29 Sep 2018
China’s Latent Opportunity for Global Health Engagement
26 September 2018
The WHO’s courtship of China reflects a desire to answer a critical concern: global health’s need for new partners and more funding. For tuberculosis control, China’s increased role in global health can be particularly effective, even if there are shortcomings.